Title:
PHARMACEUTICAL COMPOSITION COMPRISING GPR40 AGONIST AND SGLT-2 INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2022/231357
Kind Code:
A1
Abstract:
Disclosed herein are a pharmaceutical composition for prevention, alleviation, or treatment of any disease selected from the group consisting of type 2 diabetes mellitus, hyperinsulinemia, impaired glucose tolerance disorder, and insulin resistance disorder, wherein the pharmaceutical composition includes a GPR40 agonist and an SGLT2 inhibitor, the GPR40 agonist being a compound represented by Formula 1, a racemate of the compound, an enantiomer of the compound, a diastereomer of the compound, or a pharmaceutically acceptable salt of the compound, the racemate, the enantiomer or the diastereomer, a method of preparing the same, and a method of treating type 2 diabetes mellitus and the like using the same.
Inventors:
YOON JONG MIN (KR)
LEE DON GIL (KR)
JE IN GYU (KR)
YOON HONG CHUL (KR)
PARK JOON TAE (KR)
AN KYUNG MI (KR)
LEE JUNG WOO (KR)
SONG HAENG JIN (KR)
HONG DA HAE (KR)
LEE DON GIL (KR)
JE IN GYU (KR)
YOON HONG CHUL (KR)
PARK JOON TAE (KR)
AN KYUNG MI (KR)
LEE JUNG WOO (KR)
SONG HAENG JIN (KR)
HONG DA HAE (KR)
Application Number:
PCT/KR2022/006120
Publication Date:
November 03, 2022
Filing Date:
April 28, 2022
Export Citation:
Assignee:
ILDONG PHARMACEUTICAL CO LTD (KR)
International Classes:
A61K31/443; A61K9/00; A61K31/7034; A61K31/7048; A61K45/06; A61P3/10
Domestic Patent References:
| WO2018030879A1 | 2018-02-15 | |||
| WO2007033002A1 | 2007-03-22 |
Foreign References:
| KR20180069718A | 2018-06-25 | |||
| US10195178B2 | 2019-02-05 | |||
| JP2019503983A | 2019-02-14 |
Attorney, Agent or Firm:
AIP PATENT & LAW FIRM (KR)
Download PDF: